HRR Mutation Testing in mPC
How might advances in testing for homologous recombination repair (HRR) gene mutations benefit your patients with metastatic castration-resistant prostate cancer (mCRPC)? This Learning Zone provides a range of resources to help you put new innovations into practice, and identify patients who may be eligible for life-prolonging treatments, including:
- An overview of the prognostic and predictive value of HRR mutations
- Barriers to equitable testing
- Expert reflections on data presented at the 2025 ASCO Annual Meeting, with Stefanie Zschäbitz and Gerhardt Attard
- Pedro Barata’s key takeaways from EAU25, plus findings on first-line treatment from ASCO GU 2025, with Karim Fazazi
- Coming soon: The patient’s perspective and expert insights to help optimize patient care, and case studies on interpretation of HRR mutation test results
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.